# A NEW PRACTICAL METHOD FOR THE PREPARATION OF $[{}^{3}H_{6}]$ -LEUKOTRIENES C<sub>4</sub> AND D<sub>4</sub>

Michel L. Belley\*, Yves Gareau and Robert J. Zamboni

Department of Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, P.O. Box 1005, Pointe Claire-Dorval, Québec, Canada H9R 4P8

David G. Ahern and Yang Hong

DuPont, NEN products 549 Albany Street, Boston, MA 02118, USA

#### Summary

A new method for the synthesis of highly deuterated or tritiated leukotrienes was developed. The higher reactivity of a terminal alkene compared to a 1,2disubstituted one permitted the selective deuteration or tritiation of the diyne 14,15,19,19,20,20-hexadehydro LTC<sub>4</sub> triester 1. After hydrolysis, LTC<sub>4</sub> was obtained in 36% overall yield. An average of seven deuterium or tritium atoms was incorporated and the specific activity of the tritiated LTC<sub>4</sub> was greater than 180 Ci/mmol. 1 was obtained from the addition of glutathione to 14,15,19,19,20,20-hexadehydro LTC<sub>4</sub> ethyl ester which was the product of a Wittig reaction between (3,8-nonanediyn-1-yl)triphenylphosphonium iodide and 5(S), 6(S), 7(E), 9(E) ethyl 5,6-epoxy-11-oxo-7,9-undecadienoate.

Key Words: Leukotriene C<sub>4</sub> (LTC<sub>4</sub>), 14,15,19,19,20,20-Hexadehydro LTC<sub>4</sub> triester, 14,15,19,19,20,20-Hexadehydro LTA<sub>4</sub> ethyl ester,  $[{}^{3}H_{6}]$ -LTC<sub>4</sub>,  $[{}^{3}H_{6}]$ -LTD<sub>4</sub>, glutathione dimethyl ester

# Introduction

In our current research program aimed at finding new leukotriene D<sub>4</sub> (LTD<sub>4</sub>) antagonists for

the treatment of diseases such as asthma and allergies<sup>1</sup>, the new drug candidates are evaluated in a

LTD4 receptor binding assay. In order to diminish the effect of non-specific binding and hence,

increase the reliability and sensitivity of the assay, radioactive LTD4 having a specific activity greater

than 150 Ci/mmol was required.

CCC 0362-4803/95/060599-11 ©1995 by John Wiley & Sons, Ltd. Received 19 December 1994 Revised 17 January 1995 Radioactive leukotrienes are usually obtained by the catalytic hydrogenation of 14,15didehydro LTA<sub>4</sub> to give  $[14,15^{-3}H_2]$ -LTA<sub>4</sub>, which can subsequently be converted to LTC<sub>4</sub>, LTD<sub>4</sub> and LTE<sub>4</sub> by known methods.<sup>1</sup> LTE<sub>4</sub> having a specific activity of 40 Ci/mmol was reported using this route.<sup>2</sup> This method was also applied to the synthesis of  $[^{3}H_{6}]$ -hepoxylin B<sub>3</sub><sup>3</sup>, which belongs to a new class of acyclic arachidonic acid metabolites, to  $[^{2}H_{4}]$ -LTA<sub>4</sub><sup>4</sup>,  $[^{2}H_{2}]$ -LTB<sub>4</sub><sup>5</sup> and the tritiated metabolites of LTE<sub>4</sub><sup>6</sup>.

Some methods for the synthesis of highly deuterated leukotrienes have been published<sup>7</sup>, but they all incorporate the deuterium atoms early in the sequence. In order to avoid the manipulation of tritiated intermediates and introduce more than six tritium atoms into  $LTC_4$  and  $D_4$ , the selective reduction of a diyne such as 1 to the triester of  $LTC_4$  2 was envisaged (Scheme 1).



# Scheme 1

#### **Results and Discussion**

The reduction of a terminal alkyne is known to be difficult to stop at the alkene stage. We believed that we might be able to reduce it completely and selectively in the presence of other internal double bonds to give 2 in a reasonable yield. The feasibility of this approach was tested on compound 3. This diyne was prepared by the addition of the lithium anion of 5-chloro-1-pentyne on ethylene oxide and then substitution via the iodide by lithium acetylide as outlined in Scheme 2. A very good selectivity and a high yield of  $\underline{4}$  were obtained with the nickel boride reduction<sup>8</sup>, but this method requires too many labelled reagents to be practical for deuteration or tritiation. Deuteration

of 3 was achieved with Lindlar's catalyst to give the hexadeuterated alkene 5 in 27% unoptimized yield. These results prompted us to test the method on 14,15,19,19,20,20-hexadehydro  $LTC_4$  1.



The synthesis of <u>1</u> is described in Scheme 3. A Wittig reaction between the known epoxyaldehyde  $2^9$  and the phosphonium salt <u>6</u> (obtained from the diynol <u>3</u>) afforded the ethyl ester of hexadehydro LTA<sub>4</sub>. Addition of glutathione dimethyl ester yielded the triester of hexadehydro LTC<sub>4</sub>].



Hydrogenation of <u>1</u> over the Lindlar's catalyst was monitored by HPLC. Using EtOAc as the reaction solvent, the product obtained was found to be almost exclusively the tetradehydro  $LTC_4$  <u>8</u> (Scheme 4). In a more polar solvent such as methanol, <u>1</u> was reduced to the desired  $LTC_4$  <u>2a</u> and two didehydro  $LTC_4$  intermediates <u>9</u> and <u>10</u> were identified in the process.



Using this procedure, the deuteration of 1 afforded the triester of  $[{}^{2}H_{6}]$ -LTC<sub>4</sub> 2b in 17% isolated yield. A better yield of  $[{}^{2}H_{6}]$ -LTC<sub>4</sub> was obtained by hydrolysis of the crude reaction mixture followed by HPLC purification.  $[{}^{2}H_{6}]$ -LTC<sub>4</sub> was shown to co-elute with LTC<sub>4</sub> in two different HPLC systems. Mass spectra showed an average of seven deuterium atoms incorporated with some allylic exchange occurring during the hydrogenation<sup>10</sup>.

Tritiation of 1 and hydrolysis of the triester afforded  $[{}^{3}H_{6}]$ -LTC<sub>4</sub>, with specific activity greater than 180 Ci/mmol.  $[{}^{3}H_{6}]$ -LTC<sub>4</sub> was then converted to  $[{}^{3}H_{6}]$ -LTD<sub>4</sub> by known enzymatic methods.<sup>1.2</sup>

This methodology should be useful for the preparation of other multiply labelled cis alkenes such as fatty acids and their metabolites and derivatives.

#### Experimental

7-CHLORO-3-HEPTYN-1-OL. At -78°C, a solution of n-butyllithium 2.4 M in hexanes (88 mL) was added to ~500 mL of ammonia and the mixture was stirred at this temperature for 20 min. To the suspension of LiNH<sub>2</sub> so obtained, a solution of 5-chloro-1-pentyne (20.10 g, 19.5 mmol) in 200 mL of THF was added dropwise from a -78°C cooled addition funnel and the suspension was stirred at -78°C for 30 min. Then, ethylene oxide (100 mL) was added and the reaction mixture was allowed to warm to room temperature and stirred for 16 hours. 25% aq. NH<sub>4</sub>OAc was then added and the product was extracted in EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub> and distilled (124-7°C / 12 mmHg). Yield: 17.5 g, 69%. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.80 (1H, t, OH), 1.96 (2H, m), 2.40 (4H, m), 3.77 (4H, m).

7-IODO-3-HEPTYN-1-OL. A mixture of 7-chloro-3-heptyn-1-ol (2.375 g, 16.2 mmol) and NaI (14.54 g, 6 equiv.) in 30 mL of acetone was heated to reflux for 12 hours. The mixture was then cooled to room temperature and 25% aq. NH<sub>4</sub>OAc was added. The product was extracted in EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub> and filtered through silica to give the pure iodide. Yield: 3.56 g, 92%. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.90-2.06 (3H, m), 2.32 (2H, m), 2.43 (2H, m), 3.29 (2H, t), 3.69 (2H, t).

3,8-NONANEDIYN-1-OL 3. To an ice cooled solution of lithium acetylide, ethylenediamine complex, (96 mg, 1.04 mmol) in 2 mL of anhydrous DMSO was added a solution of 7-iodo-3-heptyn-1-ol (89 mg, 373  $\mu$ mol) in 0.5 mL of DMSO and the mixture was stirred at room temperature for an hour. 25% aq. NH<sub>4</sub>OAc was then added and the product was extracted with ether, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and purified by flash chromatography on silica with EtOAc:hexane 20:80. Yield: 35 mg, 69%. <sup>1</sup>H NMR (CD<sub>3</sub>COCCD<sub>3</sub>)  $\delta$  1.65 (2H, m), 2.18-2.35 (7H, m), 3.58 (2H, td), 3.76 (1H, t, OH).

3-NONEN-1-OL 4. Nitrogen was bubbled into a suspension of Ni(OAc)<sub>2</sub>•4H<sub>2</sub>O (58 mg) in 1 mL 95% EtOH. A 0.5 M suspension of NaBH<sub>4</sub> in 95% EtOH (465  $\mu$ L) was then added, followed by 23  $\mu$ L of ethylenediamine and the mixture was stirred for ~5 min. The bubbling of N<sub>2</sub> was stopped and a solution of 3,8-nonanediyn-1-ol <u>3</u> (30.2 mg, 222  $\mu$ mol) in 1 mL of 95% EtOH was added. The mixture was stirred vigourously under an atmosphere of hydrogen for 2.5 h. CH<sub>2</sub>Cl<sub>2</sub> was added and the mixture was filtered through silica with EtOAc:hexane 40:60. Purification of the product by HPLC ( $\mu$  Porasil column, 12 mm diameter, flow rate 8.9 mL/min) with EtOAc:hexane 15:85 yielded 23 mg (71%) of 3-nonen-1-ol. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.89 (3H, t), 1.23-1.43 (6H, m), 1.53 (1H, s, OH), 2.07 (2H, td), 2.34 (2H, td), 3.64 (2H, t), 5.38 (1H, td), 5.57 (1H, td).

[3,4,8,8,9,9-<sup>2</sup>H<sub>6</sub>]-3-NONEN-1-OL <u>5</u>. A mixture of 3,8-nonanediyn-1-ol <u>3</u> (17.1 mg), 50  $\mu$ L of pyridine and 8.8 mg of Lindlar's catalyst in 10 mL of hexane was stirred under an atmosphere of deuterium for 40 min. CH<sub>2</sub>Cl<sub>2</sub> was added and the mixture was filtered through silica with EtOAc:hexane 40:60. The product was purified by HPLC (12 mm diameter  $\mu$  Porasil column, flow rate 8.9 mL/min) with EtOAc:hexane 15:85. Yield 5 mg, 27%. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.86 (1H, m), 1.23-1.46 (4H, m), 2.07 (1H, s, OH), 2.07 (2H, t), 2.34 (2H, t), 3.66 (2H, t).

9-IODO-1,6-NONANEDIYNE. At -78°C, methanesulfonyl chloride (310 µL, 1.2 equiv.) and triethylamine (740 µL, 1.6 equiv.) were added successively to a solution of 3,8-nonanediyn-1-ol 3 (452 mg, 3.32 mmol) in 16 mL of CH<sub>2</sub>Cl<sub>2</sub> and the reaction mixture was allowed to stir at room temperature for an hour. 25% aq. NH<sub>4</sub>OAc was then added and the mesylate was extracted in CH<sub>2</sub>Cl<sub>2</sub>, dried over Na<sub>2</sub>SO<sub>4</sub> and purified by filtration through silica with EtOAc:hexane 15:85 and 30:70. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.70 (2H, tt), 1.96 (1H, t), 2.29 (4H, m), 2.62 (2H, tt), 3.04 (3H, s), 4.27 (2H, t). A mixture of this mesylate and sodium iodide (2.55 g, 5 equiv.) in 11 mL of acetone was heated to reflux for 2 hours. At room temperature, CH<sub>2</sub>Cl<sub>2</sub> was added and the product was filtered through silica with EtOAc. The organic solution was washed with 25% aq. NH<sub>4</sub>OAc and sodium bisulfite and was dried over Na<sub>2</sub>SO<sub>4</sub>. The iodide was purified by flash chromatography on silica with hexane and EtOAc:hexane 2.5:97.5. Yield: 750 mg, 91%. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.74 (2H, tt), 1.97 (1H, t), 2.24-2.40 (4H, m), 2.75 (2H, tt), 3.23 (2H, t).

3,8-NONANEDIYN-1-YL TRIPHENYLPHOSPHONIUM IODIDE <u>6</u>. A mixture of 9iodo-1,6-nonanediyne (750 mg, 3.05 mmol) and triphenylphosphine (1.26 g, 1.5 equiv.) was heated to reflux in 6 mL of CH<sub>3</sub>CN for 3 hours. Ether was added and an oil separated. The oil was washed twice with ether and dried. Yield: 1.43 g, 90%. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.42 (2H, tt), 1.91 (2H, br t), 1.97 (1H, t), 2.13 (2H, td), 2.83 (2H, br td), 3.92 (2H, td), 7.65-7.92 (15H, m).

GLUTATHIONE, REDUCED, DIMETHYL ESTER. A mixture of 4.51 g of glutathione, reduced, and 23 mL of 2N HCl in MeOH was stirred at room temperature overnight. The reaction mixture was then added slowly to cold aq. 25% NH<sub>4</sub>OAc and the pH was adjusted to 9 with NaOH. The product was extracted with EtOAc:THF 1:1 five times, dried over Na<sub>2</sub>SO<sub>4</sub> and purified by flash chromatography on silica with a gradient of MeOH:CH<sub>2</sub>Cl<sub>2</sub>:NH<sub>4</sub>OH 2.5:97.5:1 to 10:90:1. Yield: 1.39 g, 28%. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.93-2.20 (2H, m), 2.29-2.43 (1H, m), 2.47-2.59 (1H, m), 2.69 (1H, dd), 3.28 (1H, dd), 3.48 (1H, dd), 3.76 (6H, s), 3.92 (1H, dd), 4.15 (1H, dd), 4.79 (1H, td), 6.94 (1H, d, NH), 7.58 (1H, br t, NH).

(5S,6S,7E,9E,11Z) ETHYL 5,6-EPOXY-7,9,11-EICOSATRIENE-14,19-DIYNOATE (or 14,15,19,19,20,20-hexadehydro LTA<sub>4</sub> ethyl ester). At -78°C, 1.6 M n-BuLi in hexane (100 µL) was added dropwise to 1.26 mL of a 0.14 M solution of (3,8-nonanediyn-1-yl)triphenylphosphonium iodide <u>6</u> in THF:HMPA 5:1 and the mixture was stirred at this temperature for 1.3 hours. A solution of 5(S), 6(S), 7(E), 9(E) ethyl 5,6-epoxy-11-oxo-7,9-undecadienoate  $7^{96}$  (34.5 mg, 145 µmol) in 1.5 mL of THF was slowly added and the stirring continued for 45 min. at -78°C and 2 hours at 0°C. Then, 25% aq. NH<sub>4</sub>OAc and triethylamine (~100 µL) were added and the product was extracted in EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub> and purified by flash chromatography on silica (deactivated with hexane:Et<sub>3</sub>N 80:20) with EtOAC:hexane:Et<sub>3</sub>N 5:95:2. Yield: 35 mg, 71%. <sup>1</sup>H NMR (CD<sub>3</sub>COCD<sub>3</sub>)  $\delta$  1.20 (3H, t), 1.48-1.80 (6H, m), 2.20-2.39 (7H, m), 2.84 (1H, td, J = 2.3, 5.3 Hz), 3.10 (2H, br d), 3.16 (1H, dd, J = 2.3, 7 Hz), 4.08 (2H, q), 5.47 (2H, td, J = 7, 10 Hz and dd, J = 7, 15 Hz), 6.08 (1H, dd, J = 10, 10 Hz), 6.30 (1H, dd, J = 10, 15 Hz), 6.57 (1H, dd, J = 15, 18 Hz).

14,15,19,19,20,20-HEXADEHYDRO LTC<sub>4</sub> DIMETHYL ETHYL ESTER <u>1</u>. To a solution of 14,15,19,19,20,20-hexadehydro LTA<sub>4</sub> ethyl ester (221 mg, 0.65 mmol) in 2 mL of MeOH and 0.5

ml of Et<sub>3</sub>N was added 1.2 mg of 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical, followed by 305 mg (1.4 equiv.) of glutathione, reduced, dimethyl ester and the mixture was stirred at room temperature for 5 hours. The solvents were evaporated and the product was purified by flash chromatography on silica with Et<sub>3</sub>N:MeOH:Hexane:EtOAc 5:7:20:80 (revelation of TLC with KMnO<sub>4</sub>) to give 368 mg (84%) of pure hexadehydro LTC<sub>4</sub> triester. This compound was kept in solution in EtOAc or MeOH containing 0.1% Et<sub>3</sub>N at -70°C. <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  1.23 (3H, t, J = 7 Hz), 1.40-1.83 (5H, m), 1.90 (1H, m), 2.07 (1H, m), 2.20-2.44 (9H, m), 2.65 (1H, dd, J = 10, 14 Hz), 2.91 (1H, dd, J = 4, 14 Hz), 3.07 (2H, br d), 3.37 (1H, dd, J = 4, 10 Hz), 3.52 (1H, dd, J = 6, 7 Hz), 3.67 (1H, m), 3.72 (6H, 2s), 3.95 (2H, AB system, J = 17 Hz), 4.10 (2H, q, J = 7 Hz), 4.55 (1H, dd, J = 4, 9 Hz), 5.43 (1H, m), 5.68 (1H, m), 6.05 (1H, t, J = 11 Hz), 6.27 (2H, m), 6.58 (1H, t), 6.58 (1Hm). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.35 (3H, t), 1.50 (2H, m), 1.59-2.07 (5H, m), 1.97 (1H, t), 2.15 (1H, m), 2.23-2.40 (7H, m), 2.47 (1H, m), 2.79 (1H, dd, J = 6, 14 Hz), 3.50 (2H, m), 3.75 (6H, 2s), 3.77(1H, m), 3.95 (1H, dd, J = 5, 22 Hz), 4.12 (3H, q), 4.12 (1H, dd, J = 22 Hz), 4.71 (1H, br q), 5.48(1H, td, J = 7, 10 Hz), 5.67 (1H, dd, J = 10, 14.0 Hz), 6.06 (1H, dd, J = 11, 11 Hz), 6.22 (1H, dd, J = 10, 14 Hz, 6.31 (1H, dd, J = 10, 14 Hz), 6.49 (1H, dd, J = 12, 14 Hz), 7.13 (1H, d, NH, J = 10) Hz), 7.42 (1H, br t, NH, J = 5 Hz). MS, m/e 676 (M+1), 446, 336, 286.

[14,15,19,19,20,20-<sup>2</sup>H<sub>6</sub>]-LTC<sub>4</sub> DIMETHYL ETHYL ESTER <u>2b</u>. To a solution of 10 mg of 1 and triethylamine (1  $\mu$ L) in 3 mL of methanol was added the Lindlar's catalyst (99 mg) and the mixture was stirred under an atmosphere of deuterium for 2.5 hours. Another portion of the Lindlar's catalyst (41 mg) was then added and the mixture was stirred for 2 hours. The deuteration was followed by HPLC (column  $\mu$ Bondapak C18, solvent MeOH:0.2% aq. NH<sub>4</sub>OAc, pH 7.0 75:25, flow rate 1.2 mL/min,  $\lambda$  280 nm). The first product formed, 14,15,19,20-tetradehydro LTC<sub>4</sub> § appeared at 9.8 min. Then 14,15 and 19,20-didehydro LTC<sub>4</sub> 9 and <u>10</u> appeared at 12.5 and 13.7 min respectively. Finally, <u>2b</u>, eluted at 19.2 min. When the reaction was completed, 2 mL of CH<sub>2</sub>Cl<sub>2</sub> were added and the mixture was filtered through celite with methanol and concentrated. The product was purified by HPLC (small cartridge NovaPak C18, solvent MeOH:0.2% aq. NH<sub>4</sub>OAc pH 6.2 84:16, flow rate 12 mL/min,  $\lambda$  280 nm), the solvents were partially evaporated and the product was extracted in EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford 4.6 mg of <u>2b</u> containing some aliphatic impurities from the column. Pure <u>2b</u> was obtained by flash chromatography on silica with NH<sub>4</sub>OH:MeOH:CH<sub>2</sub>Cl<sub>2</sub> 1:10:330 and 1:10:160. Yield 1.7 mg, 17%. <sup>1</sup>H NMR (CDCl<sub>3</sub> characteristic peaks)  $\delta$  0.84 (1H, m, CHD<sub>2</sub>), 3.75 (6H, s), 4.13 (2H, q), 4.72 (1H, br q), 5.45 (1H, br q), 5.66 (1H, dd), 6.03 (1H, t), 6.27 (2H, m), 6.56 (1H, dd), 7.08 (1H, NH, br d), 7.38 (1H, NH, br t). MS, m/e (relative intensity) 694.5 (0.58, 693.5 (1.25), 692.5 (1.28), 691.5 (1.47), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 686.4 (1.03), 690.5 (2.67), 689.4 (M+1, 4.42), 687.4 (2.36), 680.4 (1.03), 690.5 (2.67), 689.4 (M+1, 4.42), 687.4 (2.36), 680.4 (1.03), 690.5 (2.67), 689.4 (4.14), 688.4 (M+1, 4.42), 687.4 (2.36), 680.4 (1.03), 690.5 (2.67), 689.4 (2.36), 686.4 (1.03).

[14,15,19,19,20,20-<sup>2</sup>H<sub>6</sub>]-LTC<sub>4</sub>. The deuteration of 1 (10 mg), was performed as previously described. The crude product was dissolved in 1 mL of MeOH and 500 µL of freshly prepared 1.0 M K<sub>2</sub>CO<sub>3</sub> and 2-3 small crystals of 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical, were added. The mixture was stirred under N<sub>2</sub> in the dark overnight. Water (-500 µL) was then added to give a clear solution and the pH was neutralized with AcOH. The product was purified by HPLC on a small cartridge Nova Pak C18 with MeOH:0.2% aq. NH<sub>4</sub>OAc pH 6.75 60:40 (flow rate 10 mL/min,  $\lambda$  280-310 nm). The methanol was evaporated and water was removed by freeze-drying to yield a white solid. Dissolution in MeOH and filtration gave 3.6 mg of [<sup>2</sup>H<sub>6</sub>]-LTC<sub>4</sub>. <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  0.87 (1H, m, CHD<sub>2</sub>), 1.10-1.53 (m), 1.60 (2H, m), 1.76 (1H, m), 1.92 (3H, s), 1.97-2.28 (m), 2.56 (2H, t), 2.70 (1H, dd), 2.95 (2H, m), 3.35 (1H, m), 3.67 (2H, m), 3.73 (2H, AB system), 4.55 (1H, dd), 5.37 (1H, br q), 5.67 (1H, dd), 6.02 (1H, t), 6.24 (2H, m), 6.58 (1H, dd). UV,  $\lambda_{max}$  280.2 nm, MS, m/e (relative intensity) 660.4 (2.31), 659.4 (2.52), 658.5 (2.62), 657.4 (4.28), 656.5 (6.05), 655.5 (M+Na, 10.41), 654.5 (9.89), 653.4 (6.40), 635.5 (4.04), 634.6 (4.70), 633.5 (7.67), 632.5 (M+1, 7.61), 631.5 (3.90), 630.4 (2.19).

[14,15,19,19,20,20-<sup>3</sup>H<sub>6</sub>]-LTC<sub>4</sub>. To a solution of 4 mg (5.9  $\mu$ mols) of 1 and 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical, (0.3 mg) in 3 ml of methanol was added the Lindlar's catalyst (75 mg) and the mixture was stirred under 1.1 atmospheres of tritium gas for 2 hours. After removal of labile tritium the reaction mixture was filtered and the crude 2c was thus obtained, 900 mCi, 85% yield based on a S.A. of 180 Ci/mmol. The crude 2c was dissolved in 10 ml methanol and 10 ml of 1M LiOH were added. The mixture was stirred under N<sub>2</sub> for 30 minutes at room temperature and was neutralized with acetic acid. The product was purified by HPLC on a  $\mu$ Bondapak C18 column, 9.4 x 250 mm, with MeOH:H<sub>2</sub>O:AcOH 65:35:0.1 (pH 5.8 adjusted with NH<sub>4</sub>OH; flow rate 3 min/ml,  $\lambda$  280 nm). The fractions containing [<sup>3</sup>H<sub>6</sub>]-LTC<sub>4</sub> were combined to afford 150 mCi of product, 14% yield.

# References

- 1. For a review on the chemistry and biology of leukotrienes, see: Rokach, J., Bioactive molecules, Vol. 11, Leukotrienes and Lipoxygenases, Elsevier, (1989).
- Cohen, N., Banner, B.L., Lopresti, R.J., Wong, F., Rosenberger, M., Liu, Y.-Y., Thom, E. and Liebman, A.A. - J. Am. Chem. Soc. <u>105</u>: 3661 (1983) and references cited.
- 3. Shevchenko, V.P., Demin, P.M., Nagaev, I.Yu., Pivnitsky, K.K., Myagkova, G.I. and Myasoedov, N.F. - Full Chemical Synthesis of [5,6,8,9,14,15-<sup>3</sup>H<sub>6</sub>]-Hepoxylin B<sub>3</sub>, 4th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, September 3-7, 1991, Toronto, Canada.
- 4. Lellouche, J.P., Aubert, F. and Beaucourt, J.P. Tetrahedron Lett., <u>29</u>: 3069 and 3073 (1988).
- 5. Leblanc, Y., Fitzsimmons, B.J., Zamboni, R. and Rokach, J. J. Org. Chem. <u>53</u>: 265 (1988).
- 6. Delorme, D., Girard, Y. and Rokach, J.- J. Org. Chem. <u>54</u>: 3635 (1989).
- Meese, C.O. J. Lab. Comp. Radiopharm. <u>23</u>: 295 (1985). Prakash, C. and Blair, I.A. - Prostaglandins, <u>37</u>: 251 (1989).
- 8. Brunet, J.J., Gallois, P. and Caubère, P. Tetrahedron Lett. 45: 3955 (1977).
- a) Corey, E.J., Clark, D.A., Goto, G., Marfat, A., Mioskoski, C., Samuelsson, B. and Hammarstrom, S. - J. Am. Chem. Soc. <u>102</u>: 1436 and 3663 (1980).

b) Rokach, J. Zamboni, R., Lau, C.K. and Guindon, Y. - Tetrahedron Lett. 22: 2759 (1981).
c) Rokach, J., Young, R.N., Kakushima, M., Lau, C.K., Séguin, R., Frenette, R. and Guindon, Y. - Tetrahedron Lett, 22:, 979 (1981).
d) Ernest, I., Main, A.J. and Menassé, R. - Tetrahedron Lett. 23: 167 (1982).

 a) Evans, E.A. - Tritium and Its Compounds, 2nd ed., Butterworths, London (1974). Evans,
 E.A., Warrell, D.C., Elvidge, J.P. and Jones, J.R. - Handbook of Tritium NMR Spectroscopy and Applications, Wiley (1985).

e) Corey, E.J. and Albright, J.O. - J. Org. Chem. 48: 2114 (1983).

b) Vader, J., Sperling, E., Kaspersen, F., Wagenaars, G. and Funke, C. - 4th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, September 3-7, 1991, Toronto, Canada.

c) Shevchenko, V.P., Nagaev, I.Yu and Myasoedov, N.F. - The Producing of Triple and Quadruple-Labelled Biologically Active Compounds by the Hydrogenation of Terminal Double Bonds, 4th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, September 3-7, 1991, Toronto, Canada.